• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect . The duration of infectiousness of individuals infected with SARS-CoV-2

tetano

Editor, Senior Moderator
J Infect


. 2020 Oct 10;S0163-4453(20)30651-4.
doi: 10.1016/j.jinf.2020.10.009. Online ahead of print.
The duration of infectiousness of individuals infected with SARS-CoV-2


Kieran A Walsh[SUP] 1 [/SUP], Susan Spillane[SUP] 2 [/SUP], Laura Comber[SUP] 2 [/SUP], Karen Cardwell[SUP] 3 [/SUP], Patricia Harrington[SUP] 2 [/SUP], Jeff Connell[SUP] 4 [/SUP], Conor Teljeur[SUP] 2 [/SUP], Natasha Broderick[SUP] 2 [/SUP], Cillian F de Gascun[SUP] 4 [/SUP], Susan M Smith[SUP] 5 [/SUP], M?ir?n Ryan[SUP] 6 [/SUP], Michelle O'Neill[SUP] 2 [/SUP]



Affiliations

Abstract

Objectives: To summarise the evidence on the duration of infectiousness of individuals in whom SARS-CoV-2 ribonucleic acid is detected.
Methods: A rapid review was undertaken in PubMed, Europe PubMed Central and EMBASE from 1 January 2020 to 26 August 2020.
Results: We identified 15 relevant studies, including 13 virus culture and 2 contact tracing studies. For 5 virus culture studies, the last day on which SARS-CoV-2 was isolated occurred within 10 days of symptom onset. For another 5 studies, SARS-CoV-2 was isolated beyond day 10 for approximately 3% of included patients. The remaining 3 virus culture studies included patients with severe or critical disease; SARS-CoV-2 was isolated up to day 32 in one study. Two studies identified immunocompromised patients from whom SARS-CoV-2 was isolated for up to 20 days. Both contact tracing studies, when close contacts were first exposed greater than 5 days after symptom onset in the index case, found no evidence of laboratory-confirmed onward transmission of SARS-CoV-2.
Conclusion: COVID-19 patients with mild-to-moderate illness are highly unlikely to be infectious beyond 10 days of symptoms. However, evidence from a limited number of studies indicates that patients with severe-to-critical illness or who are immunocompromised, may shed infectious virus for longer.

Keywords: COVID-19; RNA; SARS-CoV-2; contact tracing; coronavirus; infectiousness; isolation; review; virus culture.
 
Back
Top Bottom